Related Experiment Video
Updated: Jun 13, 2026
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening
Luis Córdova-Bahena1,2,3, Axel A Sánchez-Álvarez1,4, Angel J Ruiz-Moreno1,5
1Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Abstract:
CK1ε is a key regulator of WNT/β-catenin and other pathways that are linked to tumor progression; thus, CK1ε is considered a target for the development of antineoplastic therapies. In this study, we performed a virtual screening to search for potential CK1ε inhibitors. First, we characterized the dynamic noncovalent interactions profiles for a set of reported CK1ε inhibitors to generate a pharmacophore model, which was used to identify new potential inhibitors among FDA-approved drugs. We found that etravirine and abacavir, two drugs that are approved for HIV infections, can be repurposed as CK1ε inhibitors. The interaction of these drugs with CK1ε was further examined by molecular docking and molecular dynamics. Etravirine and abacavir formed stable complexes with the target, emulating the binding behavior of known inhibitors. However, only etravirine showed high theoretical binding affinity to CK1ε. Our findings provide a new pharmacophore for targeting CK1ε and implicate etravirine as a CK1ε inhibitor and antineoplastic agent.
Insights
Researchers identified potential cancer-fighting drugs by screening FDA-approved medications. The study found that etravirine, an HIV drug, shows promise as a casein kinase 1 epsilon (CK1ε) inhibitor and potential antineoplastic agent.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Casein kinase 1 epsilon (CK1ε) is crucial in WNT/β-catenin signaling, implicated in tumor progression.
- CK1ε is a significant therapeutic target for novel antineoplastic treatments.
- Targeting CK1ε offers a promising strategy for cancer therapy development.
Purpose of the Study:
- To identify novel CK1ε inhibitors through virtual screening of FDA-approved drugs.
- To explore the repurposing of existing medications for cancer treatment by targeting CK1ε.
- To develop a new pharmacophore model for CK1ε inhibition.
Main Methods:
- Virtual screening of FDA-approved drugs against CK1ε.
- Generation of a pharmacophore model based on known CK1ε inhibitor interactions.
- Molecular docking and molecular dynamics simulations to assess drug-target interactions.
- Evaluation of binding affinity and stability of potential inhibitors.
Main Results:
- Etravirine and abacavir, HIV medications, were identified as potential CK1ε inhibitors.
- Both drugs formed stable complexes with CK1ε, mimicking known inhibitor binding.
- Etravirine demonstrated a high theoretical binding affinity to CK1ε.
- A novel pharmacophore for CK1ε targeting was established.
Conclusions:
- Etravirine is a promising candidate for CK1ε inhibition and antineoplastic therapy.
- Drug repurposing can identify novel therapeutic agents for cancer.
- The study provides a new pharmacophore for targeting CK1ε in cancer treatment.
